Reliance Industries-subsidiary Reliance Digital Health, with Synchron Inc, signed the agreement to acquire a 2.25% stake in the Series C financing round.
- India’s Trade Deficit Widened in August as Exports Slump and Imports Surge to Record High
- Manba Finance IPO GMP, Open & Close Date, IPO Details, and Company Overview
- IT Stocks Weigh on Nifty 50, Sensex as Fed Rate Decision Nears
- Tata Power Arm Secures 400 MW Hybrid Project in Maharashtra; Shares Drop 1%
- Deflation in China Can Result in Unexpected Gains for India
The company has been developing the BCI platform, which avoided craniotomy in 2012 by using minimally invasive procedures. The Synchron Switch BCI received FDA Breakthrough Device Designation in Australia and the US in 2020.
On December 15, to raise funds after an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Bezos Expeditions, Gates Frontier, Reliance Digital Health Limited, Moore Strategic Ventures, Greenoaks, Alumni Ventures, and Project X join ARCH as new additional investors.
NeuroTechnology Investors, Khosla Ventures, Forepont Capital Partners, METIS, ID8 Investments University of Melbourne and Shanda Group are already in existence. The Series C funding brings the total funds raised since inception to $145 million. On BSE, RIL’s shares hit a high of 0.92% to Rs 2602.40.